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Abstract
 
Because tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) preferentially induces
 
apoptosis in tumor cells and plays a critical role in tumor surveillance, its receptor is an attractive
target for antibody-mediated tumor therapy. Here we report that a monoclonal antibody
(mAb) against the mouse TRAIL receptor, DR5, exhibited potent antitumor effects against
TRAIL-sensitive tumor cells in vivo by recruiting Fc receptor–expressing innate immune cells,
with no apparent systemic toxicity. Administration of the agonistic anti-DR5 mAb also signifi-
cantly inhibited experimental and spontaneous tumor metastases. Notably, the anti-DR5 mAb-
 
mediated tumor rejection by innate immune cells efficiently evoked tumor-specific T cell
immunity that could also eradicate TRAIL-resistant variants. These results suggested that the
antibody-based therapy targeting DR5 is an efficient strategy not only to eliminate TRAIL-
sensitive tumor cells, but also to induce tumor-specific T cell memory that affords a long-term
protection from tumor recurrence.
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Introduction
 
TNF-related apoptosis-inducing ligand (TRAIL) is a type II
transmembrane protein belonging to the TNF family, which
preferentially induces apoptotic cell death in a wide variety
of transformed cells but not in normal cells (1–3). We have
recently demonstrated a substantial role for TRAIL in tumor
immune surveillance as a natural suppressor of metastasis in
the liver and chemically induced or spontaneous tumor
 
development (4–6). Moreover, we also found that IFN-
 
 
 
–
mediated TRAIL induction on NK cells played a critical role
 
in the antimetastatic effects of IL-12 and 
 
 
 
-galactosylceramide
(7). Thus, endogenously expressed TRAIL appears to be a
key effector molecule for the immune surveillance and
immunotherapy of tumors (8, 9).
Preclinical studies in mice and nonhuman primates have
shown that the administration of recombinant soluble
forms of TRAIL suppressed the growth of TRAIL-sensitive
human tumor xenografts, with no apparent systemic toxicity
(10–12). This supported the potential utility of recombinant
TRAIL as a cancer therapeutic. An agonistic mAb specific
for death-inducing TRAIL receptors (TRAIL-R1/DR4
and TRAIL-R2/DR5 in humans and mTRAIL-R2/DR5
 
in mice) might be more effective for tumor eradica-
tion because the decoy receptors (TRAIL-R3/DcR1 and
TRAIL-R4/DcR2 in humans and mDcTRAILR1 and
mDcTRAILR2 in mice) have been proposed as the key
modulators of TRAIL-mediated cytotoxicity (13, 14).
However, anti-DR4 or anti-DR5 mAbs might be more
toxic because the decoy receptors have also been impli-
cated in protection of normal cells from TRAIL. It has
recently been reported that agonistic anti–human DR4 or
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DR5 mAbs exhibited potent tumoricidal activities against
human tumor xenografts in nude or SCID mice (15, 16).
However, these studies could not address the potential tox-
icity of anti-DR4 and anti-DR5 mAbs in vivo or their ef-
fects on host immunity because the mAbs were not reac-
tive with mouse DR5 on normal tissues and the therapy
was performed in immunodeficient mice. In this study, we
have examined the antitumor effects of an anti–mouse
DR5 mAb, MD5-1, against syngeneic tumor growth and
metastasis in immunocompetent mice. This mAb not only
inhibited the growth of TRAIL-sensitive tumor cells in
vivo without toxicity, but also primed tumor-specific T
cells that could eradicate TRAIL-resistant variants. The
critical contribution of FcR-bearing innate immune cells to
these processes was revealed.
 
Materials and Methods
 
Mice.
 
BALB/c and CB17-scid (SCID) mice at 6 wk of age
were from Charles River Japan Inc. and The Walter and Eliza
Hall Institute of Medical Research. IFN-
 
 
 
–deficient (IFN-
 
 
 
 
 
/
 
 
 
),
perforin-deficient (perforin
 
 
 
/
 
 
 
), or TRAIL-deficient (TRAIL
 
 
 
/
 
 
 
)
BALB/c mice and RAG-2–deficient (RAG-2
 
 
 
/
 
 
 
) C57BL/6
mice were derived as previously described (4–7). FcR common
 
  
 
chain–deficient (FcR
 
 
 
 
 
/
 
 
 
) or Fc
 
 
 
RIIB-deficient (Fc
 
 
 
RIIB
 
 
 
/
 
 
 
)
BALB/c mice were from Taconic (17, 18). All mice were main-
tained under specific pathogen-free conditions and used in ac-
cordance with the institutional guidelines of Juntendo Univer-
sity and Peter MacCallum Cancer Centre. Animal care was
provided in accordance with the procedures outlined in the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
 
Antibodies.
 
Anti–mouse CD16/32 (FcR) mAb (2.4G2), anti–
mouse CD11b mAb (5C6), control hamster Ig (UC8-1B9), anti–
mouse CD4 mAb (GK1.5), anti–mouse CD8 mAb (53-6.7),
anti–mouse FasL mAb (MFL3), and anti–mouse TRAIL mAb
(N2B2) were prepared in our laboratory as previously described
(4, 19). Biotinylated anti–mouse F4/80 mAb (A3-1) was pur-
chased from Caltag, biotinylated anti–mouse CD205 mAb
(NLDC-145) was purchased from Cedarlane Laboratories, and
biotinylated rat IgG2a
 
  
 
(R35-95) and rat IgG 2b
 
  
 
(A95-1) were
purchased from BD Biosciences. A hamster IgG2 anti–mouse
DR5 mAb (MD5-1) was generated by immunizing an Armenian
hamster with mouse DR5-Ig fusion protein (DakoCytomation),
fusing the splenocytes with P3U1 mouse myeloma cells, and then
screening the reactivity to mouse DR5-transfected BHK (BHK-
mDR5) cells by flow cytometry. MD5-1 was purified from as-
cites using a protein G column. Biotinylation was performed as
previously described (20). Requests for MD5-1 should be ad-
dressed to H. Yagita (hyagita@med.juntendo.ac.jp).
 
Tumor Cell Lines.
 
TRAIL-sensitive 4T1 mammary carci-
noma, TRAIL-resistant Fc
 
 
 
RIIB-expressing A20 B lymphoma
and P815 mastocytoma, and TRAIL-resistant L5178Y T lym-
phoma have been described (4, 6, 18, 21). TRAIL-sensitive
R331-mock renal carcinoma and TRAIL-resistant R331–FLICE
inhibitory protein (FLIP) transfectants were prepared as previ-
ously described (22). Mouse Fas- or mouse Fn14-transfected
L5178Y cells were prepared as previously described (23).
 
Flow Cytometric Analysis.
 
Immunofluorescent staining with
biotinylated mAb and flow cytometric analyses were performed
as previously described (4).
 
Cytotoxicity Assay.
 
Cytotoxic activity was tested by a 4-h
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Cr release assay as previously described (4, 5). Susceptibility of
tumor cells to TRAIL-mediated cytotoxicity was examined us-
ing murine TRAIL-transfected 2PK-3 (mTRAIL/2PK-3) or
mock-transfected 2PK-3 (mock/2PK-3) as the effector cells (4,
5). Susceptibility to MD5-1 cytotoxicity was tested in the pres-
ence of FcR-expressing P815 cells, NK cells, or macrophages.
Splenic NK cells and peritoneal exudate macrophages were pre-
pared from RAG-2
 
 
 
/
 
  
 
or FcR
 
 
 
 
 
/
 
  
 
mice as previously described
(4, 24). In some experiments, the cytotoxicity assay was per-
formed in the presence of 10 
 
 
 
g/ml anti-FcR mAb, 10 
 
 
 
g/ml
z-VAD-fmk (Peptide Institute), or 5 nM concanamycin A
(CMA; Wako Pure Chemicals). In some experiments, the indi-
cated amount of biotinylated MD5-1 was cross-linked with 5
 
 
 
g/ml streptavidin (Wako Pure Chemicals) or unlabeled
MD5-1 was cross-linked with effector cells fixed with 1% para-
formaldehyde (25). Data are represented as the mean 
 
  
 
SE of
triplicate samples.
 
Complement-mediated Lysis.
 
Complement-mediated lysis with
rabbit serum (Low-Tox M; Cedarlane Laboratories) or mice se-
rum was performed as previously described (26). As a positive
control, freshly isolated splenocytes were lysed after incubation
with anti-Thy1.2 mAb (J1j).
 
Histological Examination.
 
Hematoxylin/eosin (H/E) staining
of paraffin-embedded liver and thymus sections was performed as
previously described (27). For immunohistochemistry, 3-
 
 
 
m cryo-
stat sections were air dried and fixed with acetone for 10 min at
4
 
 
 
C. Endogenous biotin was blocked by Avidin/Biotin Blocking
Kit (Vector Laboratories). The sections were then incubated with
an appropriate concentration of primary antibody followed
by detection using the avidin-biotinylated peroxidase complex
method (ABC; Vector Laboratories). CD205 (DEC205) was de-
tected by further amplification with biotinylated tyramide (Per-
kinElmer) according to the manufacturer’s instructions.
 
Serum Transaminases.
 
Naive BALB/c mice were i.p. injected
with MD5-1 or control Ig (300 
 
 
 
g/mouse) three times at 3-d in-
tervals, and then the sera were collected from individual mice 2,
8, 20, 48, and 72 h after the last injection. Serum transaminase
(alanine aminotransferase [ALT] and aspartate aminotransferase
[AST]) activities were measured by the standard photometric
method using Hitachi type 7350 automatic analyzer.
 
Subcutaneous Tumor Growth.
 
Mice were inoculated with the
indicated number of 4T1 cells or R331-mock cells s.c. in the
hind frank, and then administered i.p. with 200 
 
 
 
g MD5-1 or
control Ig on days 0, 4, and 8. Some groups of mice were also
treated i.p. with 300 
 
 
 
g anti-CD11b mAb and/or 50 
 
 
 
g anti-
asialo GM1 (ASGM1) Ab (Wako Pure Chemicals) on days 
 
 
 
1, 4,
9, and 13. In some experiments, mice were inoculated with 2 
 
 
 
10
 
4 
 
4T1 cells, and then 200 
 
 
 
g MD5-1 were i.p. injected five
times at 3-d intervals starting at day 15 or 25. Tumor size was
measured periodically as previously described (5). Data are repre-
sented as the mean 
 
  
 
SE of five mice in each group.
 
Assessment of Tumor-specific T Cell Immunity.
 
Wild-type
BALB/c or SCID mice were inoculated with the indicated num-
ber of 4T1 cells in the mammary gland and administered i.p. with
200 
 
 
 
g MD5-1 or control Ig on days 0, 4, and 8. The MD5-1–
treated tumor-free mice were then rechallenged with 5 
 
  
 
10
 
3
 
4T1 or R331-mock cells s.c. in the opposite flank on day 42.
Some groups of these mice were administered i.p. with 100 
 
 
 
g
anti-CD4 and/or anti-CD8 mAb on 0, 4, 7, and 11 d after the
rechallenge. Effective depletion of CD4
 
  
 
and/or CD8
 
  
 
T cells
was verified by flow cytometry. As a control, naive mice were
challenged with the same number of 4T1 or R331-mock cells. As 
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another control, naive mice were inoculated s.c. with 5 
 
  
 
10
 
5 
 
ir-
radiated (20,000 rad) 4T1 cells resuspended in serum-free RPMI
1640 medium after preincubation with 10 
 
 
 
g/ml MD5-1 or con-
trol Ig and rechallenged with 5 
 
  
 
10
 
3 
 
or 2 
 
  
 
10
 
5 
 
live 4T1 cells on
day 42. In adoptive transfer experiments, 5 
 
  
 
10
 
7 
 
nylon wool–
purified T cells from the spleens of naive mice or the mice that
had rejected 4T1 after MD5-1 treatment were i.v. injected into
naive SCID mice 2 d after 4T1 (5 
 
  
 
10
 
3
 
) inoculation into mam-
mary fat pad. Data are represented as the mean 
 
  
 
SE of five to
seven mice in each group.
In another set of experiments, wild-type or perforin
 
 
 
/
 
 
 
BALB/c mice were s.c. inoculated with 10
 
4 
 
R331-mock or
R331-FLIP cells and i.p. administered with 200 
 
 
 
g MD5-1 or
control Ig on days 0, 4, and 8. As a control, naive mice were in-
oculated with 5 
 
  
 
10
 
5 
 
irradiated (20,000 rad) R331-mock cells
and rechallenged with 10
 
4 
 
live R331-mock cells on day 42. The
mice that had rejected R331-mock cells after MD5-1 treatment
were then rechallenged with 10
 
4 
 
R331-mock or R331-FLIP cells
s.c. in the opposite flank on day 35. Some groups were depleted
of CD8
 
  
 
and/or CD4
 
  
 
T cells as described above or i.p. adminis-
tered with 300 
 
 
 
g anti-FasL mAb and/or anti-TRAIL mAb on
0, 1, and 7 d after the rechallenge. To determine the kinetics of T
cell priming, mice were inoculated with 10
 
4 
 
R331-mock cells
followed by 200 
 
 
 
g MD5-1 on days 0, 4, and 8, and then 10
 
4
 
R331-FLIP cells were inoculated into the opposite flank on days
0, 7, 14, or 21. To determine the strength of T cell–mediated re-
jection, the indicated numbers of R331-mock or R331-FLIP
cells were inoculated into mice 48 d after they had rejected
R331-mock cells after MD5-1 treatment. Naive or irradiated
R331-mock–inoculated mice were similarly challenged as the
controls.
 
CTL Assay.
 
BALB/c mice were immunized with 10
 
5 
 
irradi-
ated (20,000 rad) 4T1 cells preincubated with 10 
 
 
 
g/ml control
Ig or MD5-1, or by rejecting 5 
 
  
 
10
 
3 
 
live 4T1 cells after treat-
ment with MD5-1. 8 wk after immunization, the mice were
challenged with 5 
 
  
 
10
 
3 
 
4T1 cells and then 6 d later splenocytes
were prepared from the immunized and naive mice. These sple-
nocytes were cultured with irradiated 4T1 cells and 5 U/ml of
human IL-2 (BD Biosciences) for 7 d. CTL activity was analyzed
by a 4-h 
 
51
 
Cr release assay against 4T1 or R331-mock cells.
 
Statistical Analysis.
 
Statistical analysis was performed by two-
sample 
 
t
 
 test for the cytotoxicity, metastasis, and tumor growth
 
data. Significant differences in tumor incidence at one time point
were determined by the Fisher’s exact test. P-values 
 
 
 
0.05 were
considered significant.
 
Online Supplemental Material.
 
Fig. S1 shows the antimetastatic
effect of MD5-1 against spontaneous metastasis of 4T1 cells and
experimental metastasis of R331 cells. Metastasis experiments
were performed as previously described (6, 22, 28) and proce-
dures are detailed in the Supplemental Materials and Methods.
Supplemental Materials and Methods and Fig. S1 are available at
http://www.jem.org/cgi/content/full/jem.20031457/DC1.
 
Results
 
Cytotoxic Activity of MD5-1 In Vitro.
 
We generated an
anti–mouse DR5 mAb, MD5-1, by immunizing a hamster
with mouse DR5-Ig fusion protein and screening mAb
that bound to mouse DR5-transfected BHK cells, but not
to mock, mouse Fas, or mouse Fn14 transfectants (Fig. 1
A). Among over 30 different types of mouse tumor cell
lines, all TRAIL-sensitive tumor cells were reactive with
MD5-1, as represented by 4T1 mammary carcinoma and
R331 renal carcinoma (Fig. 1 A). Conversely, all MD5-1
 
 
 
tumor cells, such as L5178Y (Fig. 1 A), were TRAIL re-
sistant. MD5-1 specifically precipitated a 44-kD protein
from TRAIL-sensitive tumor cell lines, which was also de-
tected by commercially available polyclonal Ab against
mouse DR5 (unpublished data). These results indicated
that MD5-1 was specific for mouse DR5.
Biotinylated MD5-1 exhibited a substantial cytotoxic
activity against 4T1 cells only when cross-linked by
streptavidin (Fig. 1 B) or when MD5-1 was immobilized
or cross-linked by anti–hamster Ig mAb (unpublished
data). MD5-1 also exhibited a high cytotoxic activity
against 4T1 cells when cross-linked by FcR on P815 cells,
which was abolished by anti-FcR mAb (2.4G2; Fig. 1 C).
By contrast, MD5-1 did not inhibit the cytotoxic activity
of mouse TRAIL (Fig. 1 D). These results indicated that
MD5-1 acted as a death-inducing agonist when it was
cross-linked.
Figure 1. Characterization of MD5-1 in
vitro. (A) Reactivity with mouse DR5, Fas,
and Fn14 transfectants and mouse tumor
cell lines. The thick histograms represent
MD5-1 staining and the thin histograms
represent control Ig staining. (B) Cytotoxic
activity of biotinylated MD5-1 against 4T1
cells in the presence ( ) or absence ( ) of
streptavidin. (C) Cytotoxic activity of
MD5-1 against 4T1 cells in the presence
of P815 cells with ( ) or without ( ) anti-
FcR mAb (2.4G2). (D) Cytotoxic activity
of mTRAIL/2PK-3 against 4T1 cells in the
presence of MD5-1 or anti-TRAIL mAb
(N2B2). (E) Effect of z-VAD-fmk on
MD5-1–mediated cytotoxicity against 4T1
tumor cells. (F) Cytotoxic activity of
MD5-1 and mTRAIL/2PK3 against
R331-mock and R331-FLIP cells. Similar
results were obtained in two or three inde-
pendent experiments.Antitumor Effects of Anti-DR5 Antibody In Vivo 440
We also examined the caspase dependence of MD5-1–
mediated cytotoxicity. The cytotoxic activity of MD5-1
induced by FcR-expressing P815 cells against 4T1 cells was
completely abrogated by the pan-caspase inhibitor z-VAD-
fmk, as was the TRAIL-mediated cytotoxicity (Fig. 1 E).
Moreover, R331 cells transfected with FLIP (R331-FIP),
which inhibits caspase 8–mediated death receptor signaling
(29, 30), were resistant to both TRAIL- and MD5-1–
mediated cytotoxicity (Fig. 1 F), despite a similar level of
DR5 expression to mock-transfected R331 (R331-mock)
cells (Fig. 1 A). Likewise, amongst 30 tumor cell lines tested
in vitro, susceptibility to MD5-1 cytotoxicity was strictly
correlated with TRAIL sensitivity (unpublished data).
Next, we examined the ability of FcR-expressing effec-
tor cells including fresh macrophages and NK cells to me-
diate MD5-1 cytotoxicity in vitro because these innate
immune cells are well-known mediators of antibody-
dependent cellular cytotoxicity (ADCC) in vivo (31, 32).
Macrophages induced MD5-1 cytotoxicity against 4T1
cells more effectively than NK cells, and both were inhib-
ited by anti-FcR mAb (Fig. 2 A). MD5-1 cytotoxicity
was also induced by NK cells in the presence or absence
of a perforin inhibitor, CMA, suggesting that MD5-1 did
not trigger the perforin-dependent ADCC by NK cells in
vitro (Fig. 2 A). Consistent with this notion, macrophages
and NK cells from perforin /  mice or FasL mutant gld
mice induced MD5-1 cytotoxicity against 4T1 cells at a
comparable level to that induced by wild-type cells (un-
published data). Importantly, A20 cells that only express
Fc RII, macrophages isolated from FcR     mice, and
paraformaldehyde-fixed FcR  cells, all triggered MD5-1–
mediated cytotoxicity, confirming that cross-linking was
sufficient to induce DR5- and caspase-mediated cell death
(Fig. 2, A and B). However, live (fresh) effector cells al-
ways induced higher levels of MD5-1 cytotoxicity than
those observed with fixed effector cells, suggesting some
contribution of ADCC, especially by macrophages (Fig. 2
A). All effector cells also triggered cytotoxicity against
R331-mock cells in the presence of MD5-1, however,
R331-FLIP cells were rather refractory (Fig. 2 B). Some
residual MD5-1 cytotoxicity against R331-FLIP cells in
the presence of macrophages or NK cells suggested that
these effector cells were capable of mediating a small part
of MD5-1–dependent cell death independently of caspase
activation. Collectively, these results indicated that MD5-1
was capable of triggering FcR-dependent cytolysis of
tumor cells in vitro by cross-linking DR5 and FcR (even
Fc RII), inducing both DR5-mediated caspase-depen-
dent cell death and caspase-independent ADCC. Notably,
MD5-1 did not kill tumor cells in the presence of rabbit
or mouse complement (Fig. 2 C). The fact that macro-
phages and NK cells effectively mediated MD5-1 cyto-
toxicity via their FcR implied a possible cytotoxic effect
of MD5-1 in vivo.
No Apparent Toxicity of MD5-1 In Vivo. Previous stud-
ies have suggested a hepatotoxicity of some forms of
TRAIL in vitro and in vivo (16, 33). However, signifi-
cantly elevated serum AST or ALT levels were not ob-
served in BALB/c mice after repeated MD5-1 administra-
tion (Fig. 3 A), nor was there obvious histological evidence
of tissue pathology in the liver and thymus (Fig. 3 B) as
well as other organs including the kidney, brain, lungs, in-
testine, and skin. Moreover, the MD5-1–treated mice did
not show any sign of systemic toxicity as estimated by body
weight, gross appearance, or behavior (unpublished data).
Antimetastatic Effect of MD5-1. Spontaneous metastasis
of 4T1 mouse mammary carcinoma inoculated into the
mammary gland is the most clinically relevant model for
Figure 2. Cytotoxic activity of MD5-1 in
the presence of FcR-bearing cells. (A) FcR-
mediated cytotoxic activity of MD5-1
against 4T1 tumor cells in the presence of
fresh or fixed effector cells. CMA was added
to inhibit perforin-dependent cytotoxicity
and 2.4G2 was used to block Fc RII and
Fc RIII. (B) Cytotoxic activity of MD5-1
against R331-mock and R331-FLIP tumor
cells in the presence of various effector cells.
(C) Cytotoxic activity of MD5-1 against
4T1 tumor cells in the presence of rabbit or
mouse complement.Takeda et al. 441
evaluating antimetastatic immunotherapies (28). After re-
section of the primary tumor, mice were i.p. administered
with MD5-1 to estimate the antimetastatic effect. Adminis-
tration of MD5-1 markedly inhibited spontaneous lung
and liver metastases as compared with control Ig, and
thereby significantly prolonged the survival (Fig. S1, A
and B, available at http://www.jem.org/cgi/content/full/
jem.20031457/DC1). It should be noted that at the time of
primary tumor resection mice harbored a massive 4T1
metastatic burden in the lungs ( 50,000 nodules) and livers
( 2,000 nodules). A comparable effect was also observed
in TRAIL /  and perforin /  mice, indicating that the an-
timetastatic effect of MD5-1 was independent of endoge-
nous TRAIL- or perforin-mediated cytotoxicity.
We also examined the effect of MD5-1 on the experi-
mental metastasis of R331-mock and R331-FLIP tumors.
As we recently reported, R331-FLIP exhibited an en-
hanced liver metastasis in the control Ig–treated mice
compared with R331-mock (22). MD5-1 administration
efficiently inhibited both lung and liver metastases of
R331-mock, but not R331-FLIP (Fig. S1 C, available at
http://www.jem.org/cgi/content/full/jem.20031457/DC1).
These results were consistent with the susceptibility of
R331-mock, but not R331-FLIP, to MD5-1 cytotoxicity
in vitro (Fig. 1 F), suggesting that the antimetastatic effect
of MD5-1 was primarily mediated by caspase-dependent
death signaling via DR5, rather than classical ADCC or
complement-mediated lysis.
Contribution of Macrophages and NK Cells to the Tumoricidal
Effects of MD5-1. Administration of MD5-1 substantially
inhibited s.c. growth of 4T1 tumors in both SCID (Fig. 4
A) and wild-type BALB/c (Fig. 4 B) mice. Depletion of
NK cells by the anti-ASGM1 Ab treatment, but not ad-
ministration of anti-CD11b mAb (5C6) that inhibits the
recruitment of macrophages (34), significantly enhanced
4T1 tumor growth in the control Ig–treated mice, indicat-
ing a substantial contribution of NK cells, but not macro-
phages, to the natural suppression of 4T1 tumor growth. In
contrast, the tumoricidal effect of MD5-1 was mostly abro-
gated by anti-CD11b treatment, but only weakly by NK
cell depletion. In the case of R331-mock cells, NK cell de-
Figure 3. No apparent toxicity of MD5-1 in vivo. (A) Serum AST and
ALT levels 20 h after MD5-1 injection. Data are represented as the mean  
SE of 10 mice. Similar results were obtained in two independent ex-
periments at several time points (not depicted). (B) Histological examination
(H/E) of liver ( 10) and thymus ( 5) from MD5-1–treated mice.
Figure 4. Contribution of macrophages
and NK cells to tumoricidal effect of
MD5-1. SCID mice (A) or wild-type
BALB/c mice (B) were s.c. inoculated
with 4T1 cells, and wild-type BALB/c
mice (C) were s.c. inoculated with R331-
mock cells. The mice were then treated
with MD5-1 (solid symbols) or control Ig
(open symbols). Some groups of mice
were treated with anti-ASGM1 Ab (trian-
gles), anti-CD11b mAb (circles), or con-
trol Igs (squares). (D) Wild-type BALB/c
mice were s.c. inoculated with 4T1 cells.
The mice were then treated with MD5-1
from day 0 ( ), 15 ( ), or 25 ( ). One
group of mice was treated with control Ig
from day 0 ( ) as the control. (E) Wild-type
(squares), TRAIL /   (circles), perforin / 
(triangles), and IFN-  /   (upside down
triangles) BALB/c mice were s.c. inocu-
lated with R331-mock cells. The mice
were then treated with MD5-1 (solid sym-
bols) or control Ig (open symbols). (F) Wild-
type (squares), FcR  /   (circles), or
Fc RII /  (triangles) BALB/c mice were
s.c. inoculated with 4T1 cells. The mice
were then treated with MD5-1 (solid sym-
bols) or control Ig (open symbols). Some groups of wild-type mice were treated with both anti-ASGM1 Ab and anti-CD11b mAb (upside down
triangles). All data are represented as the mean   SE of 5–10 mice. Similar results were obtained in two or three independent experiments.Antitumor Effects of Anti-DR5 Antibody In Vivo 442
pletion did not affect the natural protection, but signifi-
cantly impaired the tumoricidal effect of MD5-1 (Fig. 4 C).
Again, the anti-CD11b treatment mostly abrogated the ef-
fect of MD5-1. We also examined the effect of MD5-1
against established tumors. The MD5-1 treatment com-
mencing on day 15 (tumor size was  10 mm2) or 25 (tu-
mor size  35 mm2) still significantly inhibited the growth
of 4T1, although the MD5-1 treatment starting on day 0
was most effective (Fig. 4 D).
To further explore the effector mechanisms, we ex-
amined the antitumor effect of MD5-1 in perforin / ,
TRAIL / , IFN-  / , FcR  / , and Fc RIIB /  mice.
In the perforin / , TRAIL / , or IFN-  /  mice, the an-
titumor effect of MD5-1 was not impaired (Fig. 4 E). Sim-
ilarly, in the Fc RIIB /  mice, MD5-1 exerted an antitu-
mor effect equivalent to that in wild-type mice. By
contrast, the antitumor effect of MD5-1 was abolished in
the FcR  /  mice (mice that lack Fc R1 and Fc RIII),
just as in the anti-ASGM1 Ab and anti-CD11b mAb-
treated wild-type mice (Fig. 4 F).
To confirm the recruitment of macrophages in tumor
rejection, we examined the tumor sections by immunohis-
tochemistry. Significantly larger numbers of infiltrating
CD11b  mononuclear cells (unpublished data), including
F4/80  macrophages and CD205  DCs, were observed at
the tumor edge in the MD5-1–treated mice as compared
with the control Ig–treated mice (Fig. 5). The MD5-1–
induced macrophage and DC infiltration into tumor was
almost completely inhibited by the anti-CD11b mAb (5C6)
treatment (Fig. 5). These results suggested that the antitu-
mor effect of MD5-1 was mainly mediated by the FcR on
macrophages, but did not depend on endogenous perforin,
TRAIL, or IFN- .
Induction of Tumor-specific T Cell Immunity by MD5-1–
mediated Tumor Rejection. Given the accumulation of APCs
such as macrophages and DCs in the tumor, we next exam-
ined whether eradication of primary tumors by the MD5-1
treatment could induce tumor-specific T cell immunity.
MD5-1 administration afforded complete rejection of low
doses of 4T1 cells in wild-type BALB/c mice (Fig. 6 A, left).
When rechallenged with 4T1 or R331-mock cells on the
opposite flank, these mice rejected 4T1 cells (Fig. 6 A, mid-
dle), but not R331-mock cells (Fig. 6 A, right). Depletion of
either CD8  T cells or CD4  T cells abrogated the second-
ary rejection, although some suppression of tumor growth
was still observed in the CD4  T cell–depleted mice (Fig. 6
A, middle). In contrast, BALB/c mice preimmunized with
the same number of irradiated 4T1 cells did not reject the
secondary challenge with live 4T1 cells (unpublished data).
MD5-1 administration afforded complete rejection of
low doses of 4T1 cells in SCID mice as well as in wild-type
BALB/c mice (Fig. 6 B, left), confirming the innate im-
mune cell-mediated primary rejection. However, these
SCID mice were no more capable of resisting the second-
ary 4T1 tumor challenge than naive SCID mice (Fig. 6 B,
middle). Adoptive transfer of splenic T cells isolated from
wild-type BALB/c mice that had rejected cells after MD5-1
treatment, but not those isolated from naive BALB/c mice,
protected SCID mice from a lethal dose of 4T1 tumor
challenge (Fig. 6 B, right). These data indicated that mem-
ory T cells reactive with 4T1 had developed during the
MD5-1–mediated primary tumor rejection.
Figure 5. MD5-1 induces infiltration
of macrophages and DCs in tumor site.
Tumor was removed 8 d after tumor in-
oculation from control Ig-, MD5-1–, or
MD5-1– and anti-CD11b mAb (5C6)–
treated mice, and then stained with H/E
( 5), anti-F4/80 mAb ( 10), or anti-
CD205 mAb ( 10). The marginal region
of s.c. tumor is shown. A massive infil-
tration of F4/80  macrophages (stained
brown) was observed in the marginal
region of tumor from MD5-1–treated
mice. The arrows are indicated to dis-
tinguish CD205  DCs from nonspecific
staining of mast cells. Representative of
five tumors in each group.Takeda et al. 443
Wild-type BALB/c mice that had been immunized with
100-fold greater number of irradiated 4T1 cells precoated
with MD5-1 developed a very poor secondary response
compared with that developed in the mice that had re-
jected live 4T1 tumor cells after MD5-1 treatment (Fig. 6
C). Moreover, 4T1 tumor cell–specific CTLs were sub-
stantially induced in the mice that had rejected live 4T1 tu-
mor cells after MD5-1 treatment, but not in the mice
that had been immunized with irradiated 4T1 cells pre-
coated with either MD5-1 or control Ig (Fig. 6 D). These
results suggested a critical contribution of MD5-1–medi-
ated apoptosis of the primary tumor to the development of
tumor-specific CTLs.
Eradication of TRAIL-resistant Variants after CTL Induction.
Next, we examined whether eradication of primary R331
tumors by MD5-1 treatment enabled the induction of
R331-specific T cell immunity. Administration of MD5-1
resulted in complete rejection of 104 R331-mock cells, but
not R331-FLIP cells, in BALB/c mice (Fig. 7 A, left). No-
tably, when rechallenged with R331-mock or R331-FLIP,
these mice rejected not only R331-mock, but also R331-
FLIP cells (Fig. 7 A, middle). A rechallenge with irrelevant
4T1 tumor cells was not rejected in these mice (unpub-
lished data). In contrast, BALB/c mice preimmunized with
50-fold greater number of irradiated R331-mock cells did
not reject the secondary challenge with live R331-mock
cells. Depletion of CD8  T cells abrogated the secondary
rejection of both R331-mock (Fig. 7 A, right) and R331-
FLIP (unpublished data). These results indicated that the
MD5-1–mediated primary rejection of R331-mock cells
induced CD8  T cell–mediated immunity that could also
eradicate MD5-1–resistant R331-FLIP cells.
Next, we examined the kinetics of the development of
T cell immunity after MD5-1 treatment. All mice receiv-
ing 104 R331-mock cells rejected their primary tumor after
MD5-1 treatment. These mice were additionally inocu-
lated with R331-FLIP cells in the opposite flank to evalu-
ate the T cell–mediated rejection (Fig. 7 B). The growth of
R331-FLIP tumor was somewhat reduced in the mice re-
jecting R331-mock cells in the opposite flank compared
with the mice receiving MD5-1 and the same dose of
R331-FLIP cells alone (Fig. 7 B, 0 day). A more significant
inhibition of R331-FLIP tumor growth was observed
when R331-FLIP was injected 1 wk after the inoculation
of R331-mock cells and commencement of MD5-1 treat-
ment (Fig. 7 B, 1 week). Complete rejection was observed
when R331-FLIP was inoculated at least 2 wk later (Fig.
7 B, 2 weeks or 3 weeks). These results suggested that
MD5-1–mediated rejection of R331-mock tumors in-
duced R331-specific T cell immunity within 1 to 2 wk.
Next, we examined the strength of the T cell–mediated
secondary rejection in comparison with the MD5-1–medi-
ated primary rejection. The T cell–mediated secondary
rejection was more powerful than the MD5-1–mediated
primary rejection in eliminating greater numbers of R331-
mock cells (Fig. 7 C). Interestingly, R331-FLIP cells were
somewhat more resistant to the secondary rejection, possi-
Figure 6. Induction of tumor-specific T cell memory by MD5-1–
mediated tumor rejection. (A) BALB/c mice were inoculated with 4T1
cells and then treated with MD5-1 mAb ( ; n   25) or control Ig ( ;
n    5) (left). Simultaneously to secondary challenge with 4T1 cells,
some mice were treated with anti-CD4 mAb ( ), anti-CD8 mAb ( ),
anti-CD4 and anti-CD8 mAbs ( ), or control Ig ( ) (middle). Naive
mice were inoculated with 4T1 cells as the control ( ). Irrelevant
R331-mock cells were inoculated into 4T1-rejecting mice ( ) or naive
mice ( ) (right). (B) BALB/c (squares) and SCID (circles) mice were
inoculated with 4T1 cells and then treated with MD5-1 mAb (solid
symbols; n   25) or control Ig (open symbols; n   5) (left). 5 wk after
the first inoculation, the MD5-1–treated BALB/c ( ) and SCID ( )
mice that had rejected 4T1 were secondarily inoculated with 4T1 cells
(middle). Naive BALB/c ( ) and SCID ( ) mice were inoculated with
4T1 cells as the control. 2 d after inoculation of 4T1 cells, some SCID
mice were i.v. transferred with splenic T cells from the MD5-1–treated
BALB/c mice that had rejected 4T1 ( ) or naive BALB/c mice ( )
(right). Naive SCID mice ( ) and MD5-1–treated wild-type BALB/c
mice that had rejected 4T1 ( ) were inoculated with 4T1 cells as the
control. (C) Naive BALB/c mice ( ), MD5-1–treated wild-type
BALB/c mice that had rejected live 4T1 ( ), BALB/c mice immunized
by irradiated 4T1 cells precoated with control Ig ( ), or BALB/c mice
immunized by irradiated 4T1 cells precoated with MD5-1 ( ) were
inoculated with the indicated number of live 4T1 tumor cells. (D) Cyto-
toxic activity of splenic T cells against 4T1 (left) or R331-mock (right)
target cells. Effector splenic T cells were prepared from BALB/c mice
that had rejected live 4T1 cells by MD5-1 treatment ( ), BALB/c mice
that had been immunized by irradiated 4T1 cells precoated with MD5-1
( ) or control Ig ( ), or naive BALB/c mice ( ). All data are repre-
sented as the mean   SE of 5–10 mice. Similar results were obtained in
three to five independent experiments.Antitumor Effects of Anti-DR5 Antibody In Vivo 444
bly due to their resistance to FasL-mediated cytotoxicity
(see below).
We finally examined the effector mechanisms responsi-
ble for T cell–mediated secondary rejection (Fig. 7 D). Al-
though MD5-1 treatment eradicated primary R331-mock
tumors in perforin /  mice just as in wild-type mice, the
secondary rejection of R331-mock cells was abrogated in
perforin /  mice (Fig. 7 D, right). Administration of a neu-
tralizing anti-FasL mAb also abrogated the secondary rejec-
tion of R331-mock cells both in wild-type and perforin / 
mice. In contrast, administration of a neutralizing anti-
TRAIL mAb did not effect the secondary rejection of
R331-mock cells in either group of mice (Fig. 7 D, middle
and right). These results indicated that the T cell–mediated
secondary rejection was mediated by perforin- and FasL-
mediated cytotoxicity.
Discussion
In this study, we have characterized the antitumor effects
of an agonistic anti–mouse DR5 mAb, MD5-1, in vivo.
The anti–mouse DR5 mAb not only inhibited s.c. growing
metastases, but also lung and liver metastases of TRAIL-
sensitive mouse tumors, without apparent systemic toxic-
ity. Moreover, for the first time, we have revealed that
anti-DR5 mAb-mediated primary rejection of TRAIL-
sensitive tumors efficiently induced tumor-specific T cell
immunity in immunocompetent hosts, which could also
eradicate TRAIL-resistant tumor variants. These results
substantiated the ability of apoptosis-inducing mAb to
stimulate adaptive antitumor immunity and the potential
utility of anti-DR5 mAb as a cancer therapeutic.
A number of previous studies have evaluated the mecha-
nism of action of antitumor mAbs, but in general the in
vivo mechanism of action remains poorly understood. Very
comprehensive in vivo studies have been performed with
mAbs reactive with erbB2 (Herceptin), CD20 (rituxan),
and melanoma antigens (17, 35, 36). These have demon-
strated the importance of FcR, ADCC, and macrophages
in primary tumor rejection, with more conjecture con-
cerning the possible role of complement (37). By contrast,
evidence for direct cytotoxic effects of these and other
mAbs in vivo is scarce. Our present approach was to target
a tumor antigen (DR5) that was capable of triggering tu-
mor cell death directly via caspase activation. Regardless of
whether we used noncytotoxic or cytotoxic effector cells
Figure 7. Induction of perforin- and FasL-mediated T cell cytotoxicity
that can also eliminate TRAIL-resistant variants. (A) BALB/c mice were
inoculated with R331-mock (squares) or R331-FLIP (circles) cells, and
then treated with MD5-1 mAb (solid symbols; n   20) or control Ig
(open symbols; n   5) (left). The cured mice were secondarily challenged
with R331-mock ( ) or R331-FLIP ( ) cells (middle). Naive mice were
inoculated with R331-mock ( ) or R331-FLIP ( ) cells, and the mice
preimmunized by irradiated R331-mock cells were inoculated with
R331-mock cells ( ) as the controls (middle). Simultaneously to the sec-
ondary challenge with R331-mock cells, some mice were treated with
anti-CD8 mAb ( ), anti-CD4 and anti-CD8 mAbs ( ), or control Ig
( ) (right). (B) R331-FLIP cells were inoculated into the left flank ( ) at
the indicated time point after R331-mock cell inoculation into the right
flank ( ) and commencement of MD5-1 treatment on day 0. As a con-
trol, R331-FLIP cells were inoculated into naive mice ( ) at the same
time as the R331-FLIP inoculation into the treated mice. (C) BALB/c
mice that had rejected R331-mock by MD5-1 treatment were second-
arily challenged with the indicated number of R331-mock or R331-FLIP
cells ( ). Naive mice were inoculated with the same numbers of R331-
mock or R331-FLIP cells and treated with MD5-1 ( ) or control Ig ( )
for comparison. (D) Wild-type (squares) or perforin /  (circles) BALB/c
mice were inoculated with R331-mock cells, and then treated with
MD5-1 mAb (solid symbols; n   20) or control Ig (open symbols; n   5)
(left). The cured mice were secondarily challenged with R331-mock
cells. Simultaneously to the secondary challenge, some wild-type (middle)
and perforin /  (right) mice were treated with anti-FasL neutralizing
mAb ( ), anti-TRAIL neutralizing mAb ( ), anti-FasL and anti-TRAIL
mAbs ( ), or control Ig ( ). Naive wild-type or perforin /  mice were
inoculated with the same number of R331-mock cells as a control ( ).
All data are represented as the mean   SE of 5–10 mice. Similar results
were obtained in two independent experiments.Takeda et al. 445
or effector cells that only expressed the nonactivatory Fc -
RII, cross-linking of DR5 by MD5-1 was sufficient to
cause caspase-dependent tumor cell death in vitro. As dem-
onstrated in vivo, the cytotoxic activity of MD5-1 against
TRAIL-sensitive tumor cells required cross-linking by
FcR-expressing innate immune cells, such as NK cells and
macrophages. Although NK cells are well-known effectors
of ADCC (31), MD5-1 did not trigger perforin-dependent
ADCC in vitro and the antimetastatic effect of MD5-1 was
not impaired in perforin /  mice. Moreover, the depletion
of NK cells only weakly impaired the tumoricidal effect of
MD5-1. These results suggested a minor contribution of
NK cells and NK cell–mediated ADCC to the antitumor
effects of MD5-1. In contrast, anti-CD11b mAb treatment
suggested a major contribution of CD11b  macrophages.
The CD11b  effector cells might also include myeloid
DCs, which also express FcR (38). Consistent with this no-
tion, augmented infiltration of F4/80  macrophages and
CD205  DCs was observed in the MD5-1–treated tumors.
The anti-CD11b treatment does not deplete macrophages
but rather inhibits Mac-1 function (34, 39), and from other
studies it is clear that Mac-1 is required for efficient ADCC
(40). We cannot formally exclude a role for ADCC in vivo
because the presence of activating FcR (Fc RI or Fc RIII
containing the FcR ), but not Fc RII, was required for
primary tumor rejection by MD5-1 in vivo. Nevertheless,
macrophages generally mediate ADCC via their produc-
tion of nitric oxides and superoxides (32). Thus, the pro-
tection of R331-FLIP tumors from MD5-1 in vivo
strongly suggested that the antitumor effects of MD5-1
were primarily mediated by the induction of caspase-
dependent apoptosis via DR5 as demonstrated in vitro,
rather than the triggering of ADCC by macrophages. Given
the inhibitory effects of FLIP expression in vitro and in
vivo and the ability of MD5-1 to engage Fc RII to trigger
tumor cell death in vitro, we suggest the possibility that ac-
tivation via the FcR  chain (and in conjunction with Mac-1)
in vivo may enhance the function and further recruitment
of FcR-expressing innate immune cells, which then con-
tribute to the development of adaptive immunity.
More importantly, no prior studies have assessed and
characterized the development of adaptive immunity sub-
sequent to primary antibody-mediated tumor rejection.
One previous study demonstrated that simply coating tu-
mor cells with antibodies to surface molecules (like synde-
can-1) promoted cross-presentation of cellular antigens by
DCs to T cells, but these studies were restricted to in vitro
analysis and the mechanism here was most likely opsonized
tumor cell phagocytosis (41, 42). It is also noteworthy that
primary induction of apoptosis in tumor cells and second-
ary induction of tumor-specific immunity has been con-
ceptually implicated, but not proven, in the therapeutic ef-
fects of anti-Her2 mAb and anti-CD20 mAb in clinical
settings (43, 44). We have now provided new and rigorous
evidence that antibody-based strategies targeting a death re-
ceptor lead to the induction of tumor-specific T cell im-
munity. Importantly, we demonstrated that death recep-
tor–mediated apoptosis efficiently evoked tumor-specific T
cell immunity against variants that were resistant to primary
rejection. Emergence of TRAIL-resistant variants is a criti-
cal problem for TRAIL-based therapy (45). Our results
have indicated that anti-DR5 mAb therapy may resolve
this problem by inducing tumor-specific CTLs that can
eliminate the variants by perforin- and FasL-mediated cy-
totoxicity. Notably, by comparison, immunization with ir-
radiated tumor cells precoated with the MD5-1 mAb did
not significantly immunize mice against the tumor. Al-
though this limitation precluded us from easily further in-
vestigating the mechanisms for the induction of adaptive
immunity, these data suggested that the active induction of
DR5-mediated tumor cell apoptosis in concert with the re-
cruitment of FcR-expressing innate immune cells was re-
quired for optimal induction of tumor-specific CTLs. It
seems likely that anti-DR5 mAb not only induces apopto-
sis in tumor cells by recruiting FcR-expressing macro-
phages and DCs, but also targets the apoptotic tumor cells
to these APCs via FcR. Then, the APCs cross-present tu-
mor antigens and induce tumor-specific CTLs (42, 46–48).
Consistent with this notion, it has been reported that the
FcR-mediated uptake of apoptotic tumor cells by DCs
could efficiently induce tumor-specific CTLs in vivo
(49, 50). Therefore, the antibody-based therapy targeting
DR5 might be an efficient strategy not only to eliminate
TRAIL-sensitive tumor cells temporarily, but also to po-
tentiate tumor-specific T cell immunity that affords a long-
term protection from tumor recurrence. Such a benefit is
yet to be established for therapeutic approaches that use the
recombinant TRAIL ligand itself.
A possible concern over the use of anti-DR5 mAb in
cancer therapy is its potential toxicity against normal tissue–
expressing DR5. Although a previous study has reported
tumoricidal activity of an agonistic anti–human DR5 mAb
against TRAIL-sensitive human tumor xenografts in SCID
mice with no hepatocellular toxicity in vitro (16), the po-
tential toxicity in vivo was not addressed because that mAb
did not cross-react with mouse DR5. In addition, it has
been reported that some preparations of recombinant
TRAIL were cytotoxic against cultured human hepatocytes
(33), keratinocytes (51), and thymocytes (52) in vitro.
However, other preparations of recombinant TRAIL were
not cytotoxic against these cells in vitro (51, 53), and no
apparent systemic toxicity was observed in mice and non-
human primates when administered in vivo (10–12). In this
study, we have been able to evaluate the potential toxicity
of targeting DR5 in vivo. We have observed no detectable
systemic or organ-specific toxicity of MD5-1 as estimated
by the behavior, body weight, gross appearance, blood
transaminase levels, and histological examination. In more
recent experiments, some mice have been treated with 300
 g MD5-1 weekly for  150 d with no signs of toxicity
(unpublished data). Consistently, DR5 expression was not
detectable on the surface of freshly isolated murine hepato-
cytes or thymocytes as estimated by flow cytometry (un-
published data). In concert with our data, it has been re-Antitumor Effects of Anti-DR5 Antibody In Vivo 446
ported that normal human hepatocytes did not express
DR5 and were totally resistant to anti–human DR5 mAb
in vitro (16). Collectively, these observations suggest that
anti-DR5 mAb might be safe as a therapeutic agent.
Our results suggested some other possible advantages of
anti-DR5 mAb treatment over the antitumor activities of
endogenous or recombinant TRAIL. First, although en-
dogenous TRAIL naturally inhibits liver metastasis, but not
lung metastasis, due to the lack of TRAIL on lung NK cells
(4, 7), anti-DR5 mAb effectively inhibited both liver and
lung metastases. Second, although endogenous IFN- /
TRAIL-mediated tumor surveillance might be disturbed
by immunosuppressive cytokines such as IL-10 and TGF- 
(54, 55), anti-DR5 mAb can exert antitumor effects in
TRAIL- or IFN- –deficient conditions. Third, anti-DR5
mAb might be more effective than recombinant TRAIL
because it can induce tumor cell apoptosis independently of
the decoy receptors that may limit the efficacy of recombi-
nant TRAIL. Moreover, mAbs are quite amenable to en-
gineering to improve their half-life (by humanization;
56–58), their agonistic activity by modification of the
antigen-binding portion or the Fc portion (56, 58), and
their ADCC by defucosylation (59). Finally and most im-
portantly, the recruitment of FcR-expressing innate im-
mune cells by anti-DR5 mAb can evoke tumor-specific
adaptive T cell immunity that also eradicates TRAIL-resis-
tant variants. A direct comparison between recombinant
TRAIL and anti-DR5 mAb approaches should be under-
taken in mice or humans when both reagents are freely
available or approved for clinical trial.
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